Opportunities to build upon enhanced competition for medicines in the marketplace

Last week, I presented at the U.S Food and Drug Administration ’s (FDA)public meeting on the Hatch-Waxman Amendments to discuss the balance between encouraging innovation in biopharmaceutical development and accelerating access to generic alternatives. The important discussion led by the FDA is part of an ongoing conversation being held across the health care spectrum on the importance of a competitive marketplace for biopharmaceuticals.

Source: The Catalyst - July 27, 2017 Category: Pharmaceuticals Authors: David Korn Tags: Safety FDA Intellectual Property REMS Source Type: news